Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year ...

The UK is launching a groundbreaking Horizon trial to see if a vaccine can help people with multiple sclerosis by targeting ...

A clinical trial testing an experimental vaccine for the Epstein-Barr virus (EBV) in people with MS is now recruiting ...

Public health researchers found no uptick in myositis associated with COVID-19 vaccines across Norway and Sweden in a controlled study, contradicting previous reports of the condition occurring in the ...

Johnson & Johnson entered into a definitive agreement to acquire Halda Therapeutics OpCo for $3.05 billion in cash. Eli Lilly announced it will pay $40 million upfront and up to $2.56 billion in a ...

Have you seen ads for the new low-dose COVID vaccine called mNEXSpike and wondered what it's all about? Us too! So we did ...

A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...

With the greater part of third quarter earnings results in the rearview mirror, investors are looking ahead to marquee ...

New capabilities strengthen U.S. production, completing Moderna’s domestic end-to-end mRNA manufacturing network More than $140 million investment will create hundreds of highly skilled ...

Investors are throwing money at quantum startups. Maybe they should be looking at a more venerable player that has a lot of ...

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look ...

Stay updated with the latest healthcare market news, including major mergers, stock movers, and policy updates.